相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
Kritika Yadav et al.
BREAST CANCER RESEARCH AND TREATMENT (2022)
Subclonal heterogeneity and evolution in breast cancer
Ioanna Mavrommati et al.
NPJ BREAST CANCER (2021)
All-FIT: allele-frequency-based imputation of tumor purity from high-depth sequencing data
Jui Wan Loh et al.
BIOINFORMATICS (2020)
Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Rina Hui et al.
CLINICAL CANCER RESEARCH (2020)
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing
Guan-Tian Lang et al.
NATURE COMMUNICATIONS (2020)
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
Pedram Razavi et al.
NATURE CANCER (2020)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer
Joshua Z. Drago et al.
CLINICAL CANCER RESEARCH (2019)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal
James X. Sun et al.
PLOS COMPUTATIONAL BIOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association Analysis of Somatic Copy Number Alteration Burden With Breast Cancer Survival
Linfan Zhang et al.
FRONTIERS IN GENETICS (2018)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer
Luigi Formisano et al.
CLINICAL CANCER RESEARCH (2017)
Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification
George Seed et al.
CLINICAL CANCER RESEARCH (2017)
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer
Andrea L. A. Wong et al.
ONCOTARGET (2016)
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial
Sarat Chandarlapaty et al.
JAMA ONCOLOGY (2016)
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Lucy R. Yates et al.
NATURE MEDICINE (2015)
Precision medicine for metastatic breast cancer-limitations and solutions
Monica Arnedos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Justin M. Balko et al.
CANCER DISCOVERY (2014)
Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer
M. T. Weigel et al.
ANNALS OF ONCOLOGY (2013)
Tumour heterogeneity in the clinic
Philippe L. Bedard et al.
NATURE (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Emerging landscape of oncogenic signatures across human cancers
Giovanni Ciriello et al.
NATURE GENETICS (2013)
The Life History of 21 Breast Cancers
Serena Nik-Zainal et al.
CELL (2012)
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection
Lucia Hernandez et al.
JOURNAL OF PATHOLOGY (2012)
The landscape of cancer genes and mutational processes in breast cancer
Philip J. Stephens et al.
NATURE (2012)
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah et al.
NATURE (2012)
Sequence analysis of mutations and translocations across breast cancer subtypes
Shantanu Banerji et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Mechanisms of Endocrine Resistance in Breast Cancer
C. Kent Osborne et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
B. K. Linderholm et al.
ANNALS OF ONCOLOGY (2009)
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
Marta Pestrin et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
VEGF receptor signalling - in control of vascular function
AK Olsson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival
KN Ogston et al.
BREAST (2003)
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy
P Bertheau et al.
LANCET (2002)
分享论文
